• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy.降低风险的输卵管切除术和卵巢切除术时机的优化。
Obstet Gynecol. 2025 Jan 1;145(1):21-30. doi: 10.1097/AOG.0000000000005781. Epub 2024 Nov 7.
2
Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.预防性输卵管切除术联合延迟卵巢切除术作为 BRCA 基因突变携带者的风险降低手术的可接受性。
Gynecol Oncol. 2014 May;133(2):283-6. doi: 10.1016/j.ygyno.2014.02.030. Epub 2014 Feb 28.
3
Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.早期输卵管切除术（输卵管切除）联合延迟卵巢切除术以改善生活质量，作为BRCA1/2突变携带者降低风险的输卵管卵巢切除术的替代方案（TUBA研究）：一项前瞻性非随机多中心研究。
BMC Cancer. 2015 Aug 19;15:593. doi: 10.1186/s12885-015-1597-y.
4
Risk-reducing early salpingectomy and delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary.降低风险的早期输卵管切除术和延迟卵巢切除术作为高危女性原发性卵巢癌一级预防的两阶段替代方案：一篇评论
BJOG. 2019 Jun;126(7):831-839. doi: 10.1111/1471-0528.15651. Epub 2019 Mar 14.
5
Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.通过早期切除输卵管和晚期卵巢切除预防卵巢癌（PROTECTOR）：一项前瞻性非随机多中心试验的方案。
Int J Gynecol Cancer. 2021 Feb;31(2):286-291. doi: 10.1136/ijgc-2020-001541. Epub 2020 Sep 8.
6
Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.BRCA1/2 致病性变异携带者中输卵管切除术联合延迟卵巢切除术与输卵管卵巢切除术联合生活质量的相关性：一项非随机对照试验。
JAMA Oncol. 2021 Aug 1;7(8):1203-1212. doi: 10.1001/jamaoncol.2021.1590.
7
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.输卵管切除术联合延迟卵巢切除术作为高风险女性降低风险的输卵管卵巢切除术替代方案，以评估预防的安全性：TUBA-WISP II 研究方案。
Int J Gynecol Cancer. 2023 Jun 5;33(6):982-987. doi: 10.1136/ijgc-2023-004377.
8
Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?输卵管切除术降低卵巢癌风险：是否是时候采用输卵管切除术单独治疗了？
J Minim Invasive Gynecol. 2021 Mar;28(3):403-408. doi: 10.1016/j.jmig.2020.09.020. Epub 2020 Oct 8.
9
Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.预防性输卵管切除术和延迟卵巢切除术作为 BRCA 基因突变携带者的替代方案。
Obstet Gynecol. 2013 Jan;121(1):14-24. doi: 10.1097/aog.0b013e3182783c2f.
10
Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation.BRCA1 种系突变患者预防性输卵管切除术后的卵巢癌。
Obstet Gynecol. 2020 Jun;135(6):1270-1274. doi: 10.1097/AOG.0000000000003864.

本文引用的文献

1
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.输卵管切除术联合延迟卵巢切除术作为高风险女性降低风险的输卵管卵巢切除术替代方案，以评估预防的安全性：TUBA-WISP II 研究方案。
Int J Gynecol Cancer. 2023 Jun 5;33(6):982-987. doi: 10.1136/ijgc-2023-004377.
2
Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.遗传性癌症综合征的级联检测：我们是否应该转向直系亲属接触？系统评价和荟萃分析。
J Clin Oncol. 2022 Dec 10;40(35):4129-4143. doi: 10.1200/JCO.22.00303. Epub 2022 Aug 12.
3
Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention.机会性输卵管切除术预防卵巢癌的结局。
JAMA Netw Open. 2022 Feb 1;5(2):e2147343. doi: 10.1001/jamanetworkopen.2021.47343.
4
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.英国卵巢癌筛查协作试验（UKCTOCS）长期随访后的卵巢癌人群筛查和死亡率：一项随机对照试验。
Lancet. 2021 Jun 5;397(10290):2182-2193. doi: 10.1016/S0140-6736(21)00731-5. Epub 2021 May 12.
5
Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada.探讨加拿大不列颠哥伦比亚省机会性输卵管切除术（salpingectomy）后早绝经的指标：一项队列研究。
Am J Obstet Gynecol. 2020 Aug;223(2):221.e1-221.e11. doi: 10.1016/j.ajog.2020.02.005. Epub 2020 Feb 15.
6
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.具有 BRCA1 或 BRCA2 突变的女性中采用癌症风险降低策略的国际趋势。
Br J Cancer. 2019 Jul;121(1):15-21. doi: 10.1038/s41416-019-0446-1. Epub 2019 Apr 11.
7
Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.卵巢癌前病变的基因组景观和进化轨迹。
J Pathol. 2019 May;248(1):41-50. doi: 10.1002/path.5219. Epub 2019 Feb 15.
8
Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada.延长机会性输卵管切除术预防卵巢癌的安全性证据：来自加拿大不列颠哥伦比亚省的队列研究。
Am J Obstet Gynecol. 2018 Aug;219(2):172.e1-172.e8. doi: 10.1016/j.ajog.2018.05.019. Epub 2018 May 28.
9
Ovarian cancer statistics, 2018.卵巢癌统计数据，2018 年。
CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
10
Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.BRCA1 或 BRCA2 基因突变女性的特定年龄段卵巢癌风险。
Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.

降低风险的输卵管切除术和卵巢切除术时机的优化。

Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy.

作者信息

Pennington Kathryn P, Pugh Stephanie L, Huh Warner, Walker Joan L, Jewell Elizabeth, Havrilesky Laura J, Carter Jeanne, Muller Carolyn Y, Drapkin Ronny, Lankes Heather A, Castellano Tara, Zamorano Abigail S, Blank Stephanie V, Kachnic Lisa A

机构信息

Alaska Women's Cancer Care, Anchorage, Alaska; the NRG Oncology Statistics and Data Management Center, the University of Pennsylvania, and NRG Oncology Philadelphia East, Philadelphia, Pennsylvania; the University of Alabama Birmingham Cancer Center, Birmingham, Alabama; the University of Oklahoma, Oklahoma City, Oklahoma; Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, and Columbia University Medical Center, MU-NCORP, New York, New York; Duke University Medical Center, Durham, North Carolina; the University of New Mexico Health Sciences Center, Albuquerque, New Mexico; The Ohio State University Wexner Medical Center, Columbus, Ohio; the Louisiana State University Health Science Center, New Orleans, Louisiana; and the University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas.

出版信息

Obstet Gynecol. 2025 Jan 1;145(1):21-30. doi: 10.1097/AOG.0000000000005781. Epub 2024 Nov 7.

DOI:10.1097/AOG.0000000000005781
PMID:39509704
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11637911/
Abstract

ClinicalTrials.gov , NCT04251052.

摘要

美国国立医学图书馆临床试验注册中心，编号NCT04251052。